Richter transformation (RT), or Richter syndrome, is defined as the transformation of chronic lymphocytic leukemia (CLL) to an aggressive B-cell lymphoma. The vast majority, up to 99%, transform into diffuse large B-cell lymphoma (DLBCL), with a small subset (<1%) becoming classical Hodgkin lymphoma. Approximately half of RT cases progress through a pathway involving dysregulation of C-MYC. High-grade B-cell lymphoma (HGBL) is a recent diagnostic category of aggressive B-cell lymphomas set forth in the updated 2017 WHO Classification of Hematopoietic and Lymphoid Tissues. HGBL with MYC and BCL2 and/or BCL6 rearrangements, formerly “double-hit” and “triple-hit” lymphomas, comprise the majority of HGBL cases. Patients with HGBL have a worse prognosis than those with diffuse large B-cell lymphoma. We present a case of RT with rearrangements of MYC and BCL6. To our knowledge, there are no reported cases of RT with a “double-hit” lymphoma genotype.
SwerdlowSH, CampoE, HarrisNL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.
YeQ, Xu-MonetteZY, TzankovA, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016;7(3):2401-16. [https://doi.org/10.18632/oncotarget.6262]. [PMID:26573234]
PillaiRK, SathanooriM, Van OssSB, SwerdlowSH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323-32. [https://doi.org/10.1097/PAS.0b013e31826cebad]. [PMID:23348205]
MaoZ, Quintanilla-MartinezL, RaffeldM, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31(10):1605-14. [https://doi.org/10.1097/PAS.0b013e31804bdaf8]. [PMID:17895764]
BarransS, CrouchS, SmithA, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-5. [https://doi.org/10.1200/JCO.2009.26.3947]. [PMID:20498406]
HornH, ZiepertM, BecherC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253-63. [https://doi.org/10.1182/blood-2012-06-435842]. [PMID:23335369]
TsimberidouAM, O’BrienS, KhouriI, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343-51. [https://doi.org/10.1200/JCO.2005.05.0187]. [PMID:16710033]
ClipsonA, BarransS, ZengN, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015;1(3):125-33. [https://doi.org/10.1002/cjp2.10]. [PMID:27347428]
TzankovA, Xu-MonetteZY, GerhardM, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958-71. [https://doi.org/10.1038/modpathol.2013.214]. [PMID:24336156]
ScottDW, MottokA, EnnishiD, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848-56. [https://doi.org/10.1200/JCO.2014.60.2383]. [PMID:26240231]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email